[go: up one dir, main page]

UY24436A1 - Formulaciones orales de paroxetina de liberación controlada y retardada - Google Patents

Formulaciones orales de paroxetina de liberación controlada y retardada

Info

Publication number
UY24436A1
UY24436A1 UY24436A UY24436A UY24436A1 UY 24436 A1 UY24436 A1 UY 24436A1 UY 24436 A UY24436 A UY 24436A UY 24436 A UY24436 A UY 24436A UY 24436 A1 UY24436 A1 UY 24436A1
Authority
UY
Uruguay
Prior art keywords
delayed
controlled
oral formulations
paroxetine
paroxetine oral
Prior art date
Application number
UY24436A
Other languages
English (en)
Inventor
Leonard Graham Stanley
Elder David Philip
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10777960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY24436(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of UY24436A1 publication Critical patent/UY24436A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polyurethanes Or Polyureas (AREA)

Abstract

Una formulación de liberación controlada o de liberación retardada contiene un inhibidor selectivo de la reabsorción de serotonina (ISRS) tal como paroxetina.
UY24436A 1995-07-20 1997-01-10 Formulaciones orales de paroxetina de liberación controlada y retardada UY24436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9514842.5A GB9514842D0 (en) 1995-07-20 1995-07-20 Novel formulation

Publications (1)

Publication Number Publication Date
UY24436A1 true UY24436A1 (es) 2001-08-27

Family

ID=10777960

Family Applications (3)

Application Number Title Priority Date Filing Date
UY24288A UY24288A1 (es) 1995-07-20 1996-07-19 Procedimiento para la preparación de una composición de liberación retardada de paroxetina
UY24436A UY24436A1 (es) 1995-07-20 1997-01-10 Formulaciones orales de paroxetina de liberación controlada y retardada
UY26242A UY26242A1 (es) 1995-07-20 2000-07-13 Nueva formulacion ley 17164

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY24288A UY24288A1 (es) 1995-07-20 1996-07-19 Procedimiento para la preparación de una composición de liberación retardada de paroxetina

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY26242A UY26242A1 (es) 1995-07-20 2000-07-13 Nueva formulacion ley 17164

Country Status (40)

Country Link
EP (2) EP1382337A1 (es)
JP (2) JP3922392B2 (es)
KR (1) KR100468351B1 (es)
CN (2) CN1117567C (es)
AP (1) AP1052A (es)
AR (1) AR003463A1 (es)
AT (1) ATE253361T1 (es)
AU (1) AU6659196A (es)
BG (1) BG64076B1 (es)
BR (1) BR9609857A (es)
CA (2) CA2227298C (es)
CY (1) CY2408B1 (es)
CZ (1) CZ294110B6 (es)
DE (1) DE69630603T3 (es)
DK (1) DK0839039T4 (es)
DZ (1) DZ2074A1 (es)
EA (2) EA003775B1 (es)
EG (1) EG23934A (es)
ES (1) ES2208757T5 (es)
GB (1) GB9514842D0 (es)
HU (1) HU228853B1 (es)
IL (1) IL122940A0 (es)
MA (1) MA23942A1 (es)
MX (1) MX9800571A (es)
MY (1) MY141373A (es)
NO (1) NO315637B1 (es)
NZ (1) NZ315006A (es)
OA (1) OA10652A (es)
PE (1) PE16098A1 (es)
PL (1) PL184987B1 (es)
PT (1) PT839039E (es)
RO (1) RO119119B1 (es)
SI (1) SI0839039T2 (es)
SK (1) SK284117B6 (es)
TR (1) TR199800077T1 (es)
TW (1) TW464513B (es)
UA (1) UA68328C2 (es)
UY (3) UY24288A1 (es)
WO (1) WO1997003670A1 (es)
ZA (1) ZA966148B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
HUP0003141A3 (en) * 1997-06-10 2001-04-28 Synthon Bv 4-phenylpiperidine derivatives, process for producing them and pharmaceutical compositions containing them
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
NZ513456A (en) 1997-07-01 2003-02-28 Pfizer Sertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders
GB9808479D0 (en) * 1998-04-22 1998-06-17 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
CA2367402C (en) 1999-03-12 2010-11-23 Basf Aktiengesellschaft Stable pharmaceutical dosage form for paroxetine anhydrate
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
JP2003500348A (ja) * 1999-05-20 2003-01-07 エラン コーポレーシヨン ピーエルシー 多粒子状制御放出選択的セロトニン再吸収阻害剤製剤
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
CA2457385A1 (en) * 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
AU2004286855B2 (en) 2003-10-29 2011-04-21 Wyeth Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
AU2005215775B2 (en) * 2004-02-13 2011-02-03 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions
WO2005107716A1 (en) * 2004-03-25 2005-11-17 Cadila Healthcare Limited Controlled release paroxetine-containing tablets based on a core and a coating
AU2006274565B2 (en) * 2005-08-02 2012-05-17 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
WO2007132344A2 (en) * 2006-05-09 2007-11-22 Aurobindo Pharma Limited Controlled release compositions of an antidepressant agent
KR100885029B1 (ko) * 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
WO2009006299A2 (en) * 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
US8822498B2 (en) 2007-09-13 2014-09-02 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
TW201010743A (en) * 2008-09-05 2010-03-16 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
SG178325A1 (en) * 2009-08-24 2012-03-29 Lundbeck & Co As H New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
CN103371982A (zh) * 2012-04-20 2013-10-30 王进京 盐酸帕罗西汀肠溶控释片新型处方组成及制备方法
CN104411368A (zh) * 2012-07-09 2015-03-11 荷兰联合利华有限公司 光防护性个人护理组合物
CN103550182B (zh) * 2013-10-29 2015-04-08 吉林省东盟制药有限公司 一种肠溶缓释组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
ES2088500T3 (es) * 1990-08-21 1996-08-16 Theratech Inc Composiciones de liberacion controlada.
EP0558679A1 (en) * 1990-11-24 1993-09-08 BEECHAM GROUP plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
WO1992019241A1 (en) * 1991-05-07 1992-11-12 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
JPH05139964A (ja) * 1991-11-14 1993-06-08 Takada Seiyaku Kk 塩酸メキシレチン腸溶性製剤
DE69429710T2 (de) * 1993-11-23 2002-08-08 Euro-Celtique S.A., Luxemburg/Luxembourg Verfahren zur Herstellung einer Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release

Also Published As

Publication number Publication date
BG102259A (en) 1998-09-30
EP1382337A1 (en) 2004-01-21
EG23934A (en) 2008-01-14
CZ294110B6 (cs) 2004-10-13
ES2208757T3 (es) 2004-06-16
AU6659196A (en) 1997-02-18
ES2208757T5 (es) 2007-12-16
CZ18398A3 (cs) 1998-06-17
NZ315006A (en) 2000-01-28
WO1997003670A1 (en) 1997-02-06
DK0839039T3 (da) 2004-03-08
OA10652A (en) 2002-09-18
CA2227298A1 (en) 1997-02-06
IL122940A0 (en) 1998-08-16
KR19990029076A (ko) 1999-04-15
NO980240D0 (no) 1998-01-19
MX9800571A (es) 1998-04-30
NO980240L (no) 1998-01-20
JP3922392B2 (ja) 2007-05-30
AP1052A (en) 2002-03-21
UA68328C2 (en) 2004-08-16
UY24288A1 (es) 1997-01-16
EA200100022A1 (ru) 2001-06-25
PL184987B1 (pl) 2003-01-31
CN1195986A (zh) 1998-10-14
TW464513B (en) 2001-11-21
BG64076B1 (bg) 2003-12-31
CN1282456C (zh) 2006-11-01
HUP9900299A3 (en) 1999-11-29
CN1515257A (zh) 2004-07-28
HUP9900299A2 (hu) 1999-09-28
MY141373A (en) 2010-04-16
SK5398A3 (en) 1998-07-08
JPH11509539A (ja) 1999-08-24
EA003775B1 (ru) 2003-08-28
BR9609857A (pt) 1999-03-16
DK0839039T4 (da) 2007-10-08
TR199800077T1 (xx) 1998-05-21
PL324553A1 (en) 1998-06-08
EP0839039B1 (en) 2003-11-05
KR100468351B1 (ko) 2005-03-16
PT839039E (pt) 2004-03-31
AR003463A1 (es) 1998-08-05
PE16098A1 (es) 1998-04-16
UY26242A1 (es) 2001-01-31
NO315637B1 (no) 2003-10-06
ZA966148B (en) 1998-01-19
DE69630603T2 (de) 2004-09-23
EP0839039A1 (en) 1998-05-06
CA2445678A1 (en) 1997-02-06
AP9801177A0 (en) 1998-01-31
HU228853B1 (en) 2013-06-28
DE69630603T3 (de) 2008-01-03
CA2445678C (en) 2009-11-24
JP2006265258A (ja) 2006-10-05
CA2227298C (en) 2003-12-09
ATE253361T1 (de) 2003-11-15
EA003508B1 (ru) 2003-06-26
SI0839039T2 (sl) 2007-10-31
DE69630603D1 (de) 2003-12-11
CY2408B1 (en) 2004-09-10
RO119119B1 (ro) 2004-04-30
EP0839039B2 (en) 2007-06-06
SI0839039T1 (en) 2004-04-30
SK284117B6 (sk) 2004-09-08
GB9514842D0 (en) 1995-09-20
MA23942A1 (fr) 1997-04-01
CN1117567C (zh) 2003-08-13
HK1010494A1 (en) 1999-06-25
EA199800140A1 (ru) 1998-10-29
DZ2074A1 (fr) 2002-07-22

Similar Documents

Publication Publication Date Title
UY24436A1 (es) Formulaciones orales de paroxetina de liberación controlada y retardada
BR0012908A (pt) Método para preparar uma composição oral estável antibacteriana contendo uma lupulona hidrogenada, e, composição oral estável antibacteriana
IS1903B (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
FI973039A7 (fi) Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
FI973279A7 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
ZA975335B (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors.
HUP9901710A3 (en) New, stable medicinal compositions for generating propellant-free aerosols
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
EP1072254A4 (en) FOOD, ORAL COMPOSITIONS AND MEDICAL COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOSIS AND PROCESS FOR PREVENTING OR TREATING PERIODONTOSIS
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
ZA961291B (en) Naphthyl compounds, intermediates, compositions, and methods.
MX9800408A (es) Sales de derivados de amidina y de inhibidor de ciclooxigenasa, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
DZ2283A1 (fr) Composition de vaccin.
FI943829L (fi) Vahaton, alussa purupehmeä purukumi
NZ333198A (en) Precipitated silicas contain an active substance for delayed release
ATE107853T1 (de) Orales, melatonin enthaltendes arzneimittel.
AU7296696A (en) Deodorising formulations containing cationic biopolymers, aluminium chlorhydrate and esterase inhibitors
FR2687933B1 (fr) Produits antimottants, compositions contenant ces produits et traitements mettant ces produits en óoeuvre.
NO308842B1 (no) Nye retinoider, anvendelse derav, og farmasøytiske preparater inneholdende dem
EE9900174A (et) Konformatsiooniliselt fikseeritud LH-RH analoogid, nende kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
ZA200110401B (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
NO20005681D0 (no) Nye formuleringer som inneholder paroxetin
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
ECSP961826A (es) Nueva formulacion
MX9203486A (es) (quinolin-2-imetoxi)indol como inhibidores de la biosintesis de leucotrienos).

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20170110